Ladenburg raised the firm’s price target on Corcept Therapeutics to $70.50 from $61 and keeps a Buy rating on the shares. The company announced the Phase 3 GRACE relacorilant trial for patients with Cushing’s syndrome met the primary endpoint in the randomized withdrawal phase, the analyst tells investors in a research note. As a result, the firm increased its probability of success on relacorilant in Cushing’s syndrome to 55% from 40%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Therapeutics price target raised to $40 from $38 at H.C. Wainwright
- Corcept Therapeutics Reveals Q1 2024 Financial Results and Update
- Corcept Therapeutics reports Q1 EPS 25c, consensus 22c
- Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
- Corcept Therapeutics completes enrollment in Phase 4 CATALYST trial